Professor CHNG Wee Joo
Prof Chng Wee Joo  | Singapore Translational Cancer Consortium (STCC)

Executive Director

Singapore Translational Cancer Consortium 


National University Cancer Institute, Singapore

Deputy Director

Cancer Science Institute of Singapore, National University of Singapore (NUS)

Haematologic Malignancy Tumour Group Leader 

National University Cancer Institute, Singapore 

Senior Consultant

Department of Haematology-Oncology

National University Cancer Institute, Singapore


Yong Loo Lin School of Medicine

National University of Singapore (NUS)

Provost's Chair Professor

Yong Loo Lin School of Medicine 

National University of Singapore (NUS)

Professor Chng Wee Joo obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. He completed his Fellowship training in haematology in Singapore before he obtained an A*STAR international fellowship in 2004 to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics.

He is a member of many international professional committees, such as American Society of Haematology Scientific Committee on Plasma Cell Neoplasia, the International Myeloma Working Group and the Asian Myeloma Network. He is also involved in a number of Grant Review Committees, Conference Organising Committee, Advisory Boards and Steering Committees of Global Clinical Trials.  He has authored more than 200 publications in many reputed journals, and actively participates in clinical trials and has delivered talks in many national and international conferences. He has won multiple awards for his research both locally and internationally including the National Medical Excellence Outstanding Clinician Scientist Award, the National Medical Research Council Senior Translational Research (STaR) Award, the National University of Singapore Young Researcher Award,  and the Celgene Future Leaders in Haematology Award.

Professor Chng's current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the ultimate aim of improving patient’s outcome and personalizing treatment.